GPER

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Retrieved on: 
Tuesday, March 21, 2023
Inflammation, Skin infection, Siliceous ooze, Civil service commission, Regeneron Pharmaceuticals, Parent, Overalls, Quality of life, Atopic dermatitis, Arthralgia, GPER, TCS, Pain, Heart, European Commission, Patient, Risk, Child, Biological soil crust, European, International development, Growth, Infant, Immunology, Ageing, MPH, Conjunctivitis, EC, Red, Human, Eosinophilia, Skin, Caregiver, Safety, Conditional sentence, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Copper, EU, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.

Key Points: 
  • “I’ve personally witnessed how this chronic skin disease can disrupt the lives of entire families when left uncontrolled.
  • Between 85% and 90% of patients first develop symptoms before 5 years of age, which can often continue through adulthood.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • “Too often the parents and caregivers of children with severe atopic dermatitis are left desperate for new treatments to manage this chronic disease.

LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Atopic dermatitis, Disease, Royal commission, Population, Review, Science, GPER, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Poster, Sleep, IGA, EASI, Research, MPH, University, Food, Adolescence, Department, Ludwig Maximilian University of Munich, Â, Leo Pharma, United Arab Emirates, Adult, Ageing, Safety, LEO, Dermatitis, DKK, EC, AD, European, European Commission, Week, Itch, FDA, Pharmaceutical industry, Vaccine, Tralokinumab, Dermatology

The European Commission decision is valid in all European Union Member States, Iceland, Norway, and Liechtenstein.

Key Points: 
  • The European Commission decision is valid in all European Union Member States, Iceland, Norway, and Liechtenstein.
  • The European Commissions approval of Adtralza for use in adolescent patients is a demonstration of our relentless commitment to bringing new treatment options to those living with atopic dermatitis, said Christophe Bourdon, Chief Executive Officer, LEO Pharma A/S.
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • Paller A. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial.

Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office

Retrieved on: 
Wednesday, September 21, 2022
Therapy, Trial of the century, Human, MD, GPER, Neoplasm, Quantum chemistry composite methods, Partnership, Patient, CEO, USPTO, Patent, Upstart, Perelman School of Medicine at the University of Pennsylvania, Multimedia, University, PCI, Penn Center, Innovation, Pharmaceutical industry, Carl Linnaeus, Cancer

HADDONFIELD, N.J., Sept. 21, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on June 28, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,369,618 ('618 patent) entitled "Compounds, Compositions Methods for Prevention and/or Treatment of Cancer".

Key Points: 
  • "We are extremely pleased that the USPTO has issued this critical patent, the third essential patent in our GPER agonist patent portfolio," commented Patrick Mooney, MD, CEO of Linnaeus.
  • "We believe that the issued claims will provide critical market protection for LNS8801 through at least 2037.
  • As we continue to collect very promising data from our clinical trials of LNS8001, we plan to prosecute the '618 patent on a worldwide basis."
  • Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors.

Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting

Retrieved on: 
Monday, June 6, 2022
Upstart, Human, Biomarker, Toxicity, CEO, Partnership, ASCO, Innovation, Toxic leukoencephalopathy, Therapy, Multimedia, University, Penn Center, Pembrolizumab, Patient, ICI, University of Pennsylvania Smell Identification Test, Infrared spectroscopy correlation table, Poster, MD, Clinical trial, Population, GPER, Neoplasm, PCI, Safety, Pharmaceutical industry, Vaccine, Carl Linnaeus

HADDONFIELD, N.J., June 6, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination with pembrolizumab in patients who have developed secondary resistance to antiPD-1/L1 therapy at the 2022 ASCO Annual Meeting.

Key Points: 
  • HADDONFIELD, N.J., June 6, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination with pembrolizumab in patients who have developed secondary resistance to antiPD-1/L1 therapy at the 2022 ASCO Annual Meeting.
  • These biomarkers are being further validated and will aid in the selection of patients in future clinical studies.
  • "We are very pleased to showcase these data at ASCO," commented Patrick Mooney, MD, CEO of Linnaeus.
  • Additionally, LNS8801 has demonstrated target engagement, c-Myc protein depletion, and clinical benefit in some patients with advanced cancer.

Linnaeus Therapeutics Announces Presentation of Pre-Clinical Data of LNS8801 at 2022 AACR Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
Penn Center, Therapy, Human, Cell death, Trial of the century, Multimedia, Upstart, AACR, Research, Doctor of Philosophy, Columbia University, Uveal melanoma, PCI, CEO, Perelman School of Medicine at the University of Pennsylvania, Columbia University Irving Medical Center, Poster, Neoplasm, Innovation, MD, ASCO, GPER, University, Patient, Partnership, Vaccine, Medical imaging, Carl Linnaeus

Ambrosini and colleagues have demonstrated that LNS8801 has potent anti-cancer activities in models of uveal melanoma cells.

Key Points: 
  • Ambrosini and colleagues have demonstrated that LNS8801 has potent anti-cancer activities in models of uveal melanoma cells.
  • "We are extremely pleased to showcase these data at AACR," commented Patrick Mooney, MD, CEO of Linnaeus.
  • "These data demonstrate that LNS8801 has activity in preclinical models of uveal melanoma in vitro and in vivo.
  • Importantly, these data are consistent with the clinical data in our on-going studies of LNS8801 in advanced cancer patients.

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma

Retrieved on: 
Wednesday, April 6, 2022
Penn Center, Therapy, National, Human, Partnership, Trial of the century, National Cancer Institute, Multimedia, Carl Linnaeus, Upstart, Cancer, Uveal melanoma, PCI, Perelman School of Medicine at the University of Pennsylvania, Neoplasm, Innovation, MD, Small business, NCI, GPER, University, Patient, Pembrolizumab, Mooney, Pharmaceutical industry

The award will help fund the clinical development of its lead compound, LNS8801, which targets a G protein-coupled receptor (GPER), for the treatment of metastatic cutaneous and uveal melanoma both as a monotherapy and in combination with pembrolizumab.

Key Points: 
  • The award will help fund the clinical development of its lead compound, LNS8801, which targets a G protein-coupled receptor (GPER), for the treatment of metastatic cutaneous and uveal melanoma both as a monotherapy and in combination with pembrolizumab.
  • "This award will allow us to further advance LNS8801 as a potentially safe and effective oral therapeutic for the treatment of metastatic cutaneous and uveal melanoma.
  • We thank the NCI for their ongoing support and belief in the potential of LNS8801 to help patients with cancer."
  • Additionally, LNS8801 has demonstrated target engagement, c-Myc protein depletion, and clinical benefit in patients with advanced cancer.

Global Scorecard Highlights Unmet Needs of Eczema Patients Worldwide And Strategies for Addressing Them

Retrieved on: 
Wednesday, April 6, 2022
Dermatitis, Organization, Caregiver, Adult, Health, Pain, Learning, Quality of life, Initiative, Anxiety, Depression, Atopic dermatitis, GPER, Patient, Partnership, Decision-making, Health insurance, Medicine

SANTA BARBARA, Calif., April 6, 2022 /PRNewswire/ -- The Global Patient Initiative to Improve Eczema Care (GPIIEC), a partnership of eleven patient organizations, today released a global report card of eczema patient care in eight countries: Australia, Canada, Denmark, France, Italy, Germany, United States, and the United Kingdom. The Initiative is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients and their caregivers, and to identify opportunities for improvement.

Key Points: 
  • New study finds low treatment satisfaction, poor control of symptoms, high psychosocial burden and shortcomings in patient centered care for eczema patients worldwide.
  • SANTA BARBARA, Calif., April 6, 2022 /PRNewswire/ -- The Global Patient Initiative to Improve Eczema Care (GPIIEC), a partnership of eleven patient organizations, today released a global report card of eczema patient care in eight countries: Australia,Canada,Denmark,France,Italy,Germany,United States, and theUnited Kingdom.
  • The Initiative is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients and their caregivers, and to identify opportunities for improvement.
  • Poorly controlled eczema that can't be fully addressed by existing treatments substantially impacts patients' health-related quality of life.

Global Scorecard Highlights Unmet Needs of Eczema Patients Worldwide And Strategies for Addressing Them

Retrieved on: 
Wednesday, April 6, 2022
Dermatitis, Organization, Caregiver, Adult, Health, Pain, Learning, Quality of life, Initiative, Anxiety, Depression, Atopic dermatitis, GPER, Patient, Partnership, Decision-making, Health insurance, Medicine

SANTA BARBARA, Calif., April 6, 2022 /PRNewswire/ -- The Global Patient Initiative to Improve Eczema Care (GPIIEC), a partnership of eleven patient organizations, today released a global report card of eczema patient care in eight countries: Australia, Canada, Denmark, France, Italy, Germany, United States, and the United Kingdom. The Initiative is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients and their caregivers, and to identify opportunities for improvement.

Key Points: 
  • New study finds low treatment satisfaction, poor control of symptoms, high psychosocial burden and shortcomings in patient centered care for eczema patients worldwide.
  • SANTA BARBARA, Calif., April 6, 2022 /PRNewswire/ -- The Global Patient Initiative to Improve Eczema Care (GPIIEC), a partnership of eleven patient organizations, today released a global report card of eczema patient care in eight countries: Australia,Canada,Denmark,France,Italy,Germany,United States, and theUnited Kingdom.
  • The Initiative is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients and their caregivers, and to identify opportunities for improvement.
  • Poorly controlled eczema that can't be fully addressed by existing treatments substantially impacts patients' health-related quality of life.

"BIG IDEAS FOR ECZEMA CHALLENGE" WINNERS ANNOUNCED

Retrieved on: 
Monday, March 28, 2022
Dermatitis, Organization, Biofeedback Certification International Alliance, First Prize, Caregiver, Adult, Skin, Association, Research, Dermatology, Prize, Regeneron Pharmaceuticals, Quality of life, Parent, Boehringer Ingelheim, Knowledge, Inflammation, Physician, Solution, Child, GPER, Patient, Pharmaceutical industry, Toy, Hospital

SANTA BARBARA, Calif., March 28, 2022 /PRNewswire/ -- Global Parents for Eczema Research and GlobalSkin - International Alliance of Dermatology Patient Organizations today announced the winners of the "Big Ideas for Eczema Challenge" contest that generated worldwide interest and received 70 submissions from 11 countries. The goal of the contest is to improve the understanding of eczema by harnessing patients' and caregivers' insights – and ultimately to accelerate the development of new treatments, management approaches and prevention strategies.

Key Points: 
  • SANTA BARBARA, Calif., March 28, 2022 /PRNewswire/ -- Global Parents for Eczema Research and GlobalSkin - International Alliance of Dermatology Patient Organizations today announced the winners of the "Big Ideas for Eczema Challenge" contest that generated worldwide interest and received 70 submissions from 11 countries.
  • The following three stand-out research ideas were chosen by a panel of experts as the winners of the 2022 Challenge:
    First Prize: Using isolated hookworm protein to trigger a re-balancing of theimmune system by Armando de la Libertad, parent of a child with eczema.
  • Second Prize:Preventing and counteracting exposure to pollutants that cause systemic oxidative damage and widespread inflammation in the skin by Nic Novak, adult with eczema.
  • "Our Big Ideas Challenge proves that the wisdom of patients can lead the way to better solutions for people with eczema," she said.

"BIG IDEAS CHALLENGE" CHAMPIONS PATIENT IDEAS FOR ECZEMA RESEARCH

Retrieved on: 
Tuesday, January 18, 2022
Association, Research, Patient, Regeneron Pharmaceuticals, Parent, Dermatitis, Biofeedback Certification International Alliance, Dermatology, Disease, Solution, Boehringer Ingelheim, Skin, Caregiver, GPER, Quality of life, Prevalence, Organization, Physician, Pharmaceutical industry, Health insurance, Hospital

SANTA BARBARA, Calif., Jan. 18, 2022 /PRNewswire/ -- Two global patient organizations launched a worldwide "Big Ideas Challenge" contest today that invites patients and families impacted by eczema to share their insights with the research community. The goal is to improve the understanding of eczema and accelerate the development of new and better treatments.

Key Points: 
  • SANTA BARBARA, Calif., Jan. 18, 2022 /PRNewswire/ -- Two global patient organizations launched a worldwide "Big Ideas Challenge" contest today that invites patients and families impacted by eczema to share their insights with the research community.
  • The goal is to improve the understanding of eczema and accelerate the development of new and better treatments.
  • "The Big Ideas Challenge creates a platform for them to share these ideas and rewards patients and caregivers who submit the best ones," she said.
  • Eczema is a chronic relapsing inflammatory skin condition that is increasing in prevalence in many countries worldwide.